Search results for " Responder"

showing 10 items of 23 documents

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-[alpha]2b: A Randomized Trial

2009

BACKGROUND Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. OBJECTIVE To evaluate use of peginterferon-alpha2a plus ribavirin to re-treat nonresponders to peginterferon-alpha2b plus ribavirin. DESIGN Randomized, parallel-group trial conducted between September 2003 and February 2007. Patients and researchers were not blinded to intervention assignment. Random assignment was centralized, computer-generated, and stratified by geographic region, hepatitis C virus (HCV) genotype, and histologic diagnosis. SETTING 106 international centers. PATIENTS 950 nonresponders to 12 or more weeks of therapy with peginterferon-alpha2b plus ribav…

Malemedicine.medical_specialtyHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawPegylated interferonInternal medicineRibavirinInternal Medicineretreatment non responder hepatitis CHumansMedicineTreatment FailureNot evaluatedbusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesSurgerychemistryRetreatmentRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct

High Responders to Hypertrophic Strength Training Also Tend to Lose More Muscle Mass and Strength During Detraining Than Low Responders.

2021

Räntilä, A, Ahtiainen, JP, Avela, J, Restuccia, J, Kidgell, DJ, and Häkkinen, K. High responders to hypertrophic strength training also tend to lose more muscle mass and strength during detraining than low responders. J Strength Cond Res 35(6): 1500-1511, 2021-This study investigated differences in individual responses to muscle hypertrophy during strength training and detraining. Ten weeks of resistance training was followed by 6 weeks of detraining in men (n = 24). Bilateral leg press (LP) one-repetition maximum (1RM) and maximal electromyography (EMGs) of vastus lateralis (VL) and vastus medialis, maximal voluntary activation (VA), transcranial magnetic stimulation for corticospinal exci…

Malemedicine.medical_specialtyHigh responderWeight LiftingVastus medialisStrength trainingPhysical Therapy Sports Therapy and RehabilitationElectromyographyMuscle massMuscle hypertrophyInternal medicinehigh and low respondersmedicinestrength trainingHumansOrthopedics and Sports MedicineMuscle StrengthLeg pressMuscle Skeletaldetrainingmedicine.diagnostic_testbusiness.industryElectromyographyResistance TrainingGeneral MedicineHypertrophyLow responderharjoitusvasteEndocrinologylihasmassavoimaharjoittelubusinesshypertrophyhuman activitieslihasvoimaJournal of strength and conditioning research
researchProduct

PS01.049: ENDOSTIM™ NON-RESPONDERS: AN ANALYSIS

2018

Abstract Background Electronic stimulation oft the lower esophageal sphincter (LES) is a new promising anti-reflux procedure that is established in Germany since 2014. Basically two leads are inserted laparoscopicaly into the LES and connected to an implantable pulse generator (IPG) which is placed in a subcutaneous pocket. This stimulation is supposed to build up the muscular anti-reflux barrier. It is limited to patients with a small hiatal hernia < 3 cm and reflux esophagitis LA Classification Type A-C. Although long-term results up to 4 years with a good postoperative reflux control and an increased quality of life have been published, no data about Endostim™ non-responders, difficul…

Non respondersmedicine.medical_specialtybusiness.industryInternal medicineGastroenterologyMedicineGeneral MedicinebusinessDiseases of the Esophagus
researchProduct

APOPTOSIS RATE IN CUMULUS CELLS AS POSSIBLE MOLECULAR BIOMARKER FOR OOCYTE COMPETENCE.

2017

Several lines of evidence showed that apoptosis rate of cumulus cells in oocytes derived by assisted reproductive technologies could be used as an indicator of fertilizing gamete quality. Aim of the study was to investigate the effects of three different ovarian stimulation protocols on the biological and clinical outcome in hyporesponder patients. Collected data showed a higher significant rate of DNA fragmentation index (DFI) in U group (patients treated with Highly Purified human Menopausal Gonadotrophin) than in P group (treated with recombinant human Follicle Stimulating Hormone (r-hFSH) combined with recombinant human Luteinizing Hormone (r-hLH)). Both groups R (treated with r-hFSH al…

Oocyte competence Granulosa cells DNA fragmentation Hormonal treatment Poor responderSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudin…

2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…

Response ratemedicine.medical_specialtyCost per responderBiologicCostIxekizumabLongitudinal StudieContext (language use)Secukinumab.Severity of Illness IndexAntibodiesIndirect costsSettore MED/35Quality of lifeInternal medicinePsoriasisUstekinumabMonoclonalAdalimumab; Ixekizumab; Antibodies Monoclonal; Longitudinal Studies; Quality of Life; Psoriasis; Treatment Outcome; Severity of Illness Index; Italy; Humans; Biological Therapy; Ustekinumab; Secukinumab; Response rate; Real-world; Ixekizumab; Cost per responder; BiologicmedicineAdalimumabHumansPsoriasisLongitudinal Studieshealth care economics and organizationsSecukinumabPsoriasiAdalimumab; Biologic; Cost per responder; Costs; Ixekizumab; Real-world; Response rate; Secukinumab; Ustekinumab; Antibodies Monoclonal; Biological Therapy; Humans; Italy; Longitudinal Studies; Severity of Illness Index; Treatment Outcome; Psoriasis; Quality of Lifebusiness.industryHealth PolicyResearchAdalimumabAntibodies Monoclonalmedicine.diseaseCostsBiological TherapyIxekizumabTreatment OutcomeReal-worldItalyQuality of LifeSecukinumabUstekinumabPublic aspects of medicineRA1-1270Settore MED/35 - MALATTIE CUTANEE E VENEREEbusinessHumanmedicine.drugBMC Health Services Research
researchProduct

A journey into the information Typhoon: Typhoon Haiyan DRL Field Report Findings and Research Insights:

2013

Supply chain magementFirst respondersCrisis managementDevastationThyfoonsResilient OrganisationsLogisticsDefence Safety and SecurityDecision supportDisastersDigital humanitariansSafety and SecurityInformation managementNO - Networked OrganisationsELSS - Earth Life and Social Sciences
researchProduct

Individuality of responses to bilateral and unilateral volume equated hypertrophic strength training in physically active men

2019

Purpose. The purpose of the present study was to investigate possible differences between unilateral and bilateral strength training during ten weeks progressive hypertrophic strength training and six weeks detraining period. Furthermore, it was examined possible different individual responders in muscle hypertrophy during strength training and, how those different responders would behave during the detraining phase following the training period. Methods. The present intervention included ten weeks of progressive hypertrophic resistance training followed by six weeks of detraining in healthy young men (n=24). Ultrasound was used to measure vastus lateralis (VL) muscle cross-sectional area (…

maximum strengthindividualityindividual responderstraininghigh respondersisometricstrength trainingunilateralharjoitteluvoimaharjoitteluhypertrophyyksilöllisyysbilaterallow responders
researchProduct

HLA antigens and immunoresponsiveness to insulin in insulin-dependent diabetes mellitus.

2008

HLA-A and B antigens were determined in 112 patient with insulin-dependent juvenile onset diabetes mellitus, who could be subdivided into “non” and “high responders” to insulin. The data revealed a trend of an association of these diabetes subgroups with only one of the diabetes-associated antigens HLA-B8 and HLA-BW15 and indicated the existence of at least two different genetic constellations for susceptibility to juvenile diabetes mellitus. One form with a strong immune-response to insulin seemed to be associated with HLA-BW 15 and the other form without humoral immunoreactivity to insulin seemed to be associated with the presence of HLA-B8 and the absence of HLA-B7.

medicine.medical_specialtyHigh respondermedicine.medical_treatmentInsulin AntibodiesImmunologyHuman leukocyte antigenBiochemistryAntigenHLA AntigensDiabetes mellitusInternal medicineHistocompatibility AntigensGeneticsmedicineDiabetes MellitusImmunology and AllergyHumansInsulinbusiness.industryInsulinGeneral Medicinemedicine.diseaseEndocrinologyInsulin dependent diabetesImmunologyJuvenile diabetes mellitusbusinessJuvenile-onset diabetes mellitusTissue antigens
researchProduct

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: Efficacy following prior methylphenidate trea…

2016

Guanfacine extended release (GXR) and atomoxetine (ATX) are nonstimulant treatments for attention-deficit/hyperactivity disorder (ADHD). As nonstimulant treatments are often used after stimulants in ADHD, GXR was assessed relative to prior stimulant treatment in a randomized controlled trial (RCT), in which ATX was included as a reference arm, and in the open-label phase of a randomized-withdrawal study (RWS). Participants were 6–17 years old with ADHD Rating Scale version IV (ADHD-RS-IV) scores ≥32 and Clinical Global Impressions – Severity scores ≥4. RCT participants received dose-optimized GXR (1–7 mg/day), ATX (10–100 mg/day), or placebo for 10–13 weeks. RWS participants received dose-o…

medicine.medical_specialtyNeuropsychiatric Disease and Treatmentmedicine.medical_treatmenteffectivenessmethylphenidateNeurosciences. Biological psychiatry. NeuropsychiatryPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialRating scalelawInternal medicinemental disordersmedicineAttention deficit hyperactivity disorderADHD0501 psychology and cognitive sciencesPsychiatryRC346-429child and adolescentguanfacineOriginal Researchbusiness.industryMethylphenidate05 social sciencesAtomoxetinetrialmedicine.disease030227 psychiatryGuanfacineinadequate respondersStimulantNeurology. Diseases of the nervous systembusinessGXRatomoxetine050104 developmental & child psychologymedicine.drugRC321-571
researchProduct

Genotype 1 Relapsers and Non‐Responders

2011

medicine.medical_specialtyNon respondersbusiness.industryInternal medicineGenotypeMedicinebusinessGastroenterologyAdvanced Therapy for Hepatitis C
researchProduct